Claims for Patent: 6,472,515

Summary for Patent: 6,472,515

Title:	Response element
Abstract:	The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.
Inventor(s):	Climent-Johansson; Isabel (Stockholm, SE), Dahlman-Wright; Karin (Bromma, SE), Lake; Staffan (Lidingo, SE), Wasserman; Wyeth (Stockholm, SE)
Assignee:	Biovitrum AB (Stockholm, SE)
Application Number:	09/645,629
Patent Claims:	1. An isolated nucleic acid sequence comprising an Afx response element, wherein the Afx response element comprises the nucleotide sequence AACATGTT, and wherein the Afx response element is contained in a promoter, intron, or intergenic sequence of the nucleic acid. 2. The nucleic acid sequence of claim 1, wherein the Afx response element is a cytokine response element. 3. The nucleic acid sequence of claim 1, wherein the Afx response element is an insulin response element. 4. A vector construct comprising the nucleic acid sequence of claim 1. 5. A host cell transformed with the vector construct of claim 4. 6. The vector of claim 4, wherein the Afx response element comprises the nucleotide sequence GTAAACATGTTGT (SEQ ID NO:34). 7. The vector of claim 4, wherein the Afx response element comprises the nucleotide sequence of any of SEQ ID NOs:1-20. 8. The vector of claim 4, wherein the Afx response element is operably linked to a nucleotide sequence encoding a protein, wherein the protein corresponds to the sequence of a naturally occurring polypeptide whose expression is regulated by insulin. 9. The vector of claim 4, wherein the Afx response element is operably linked to a nucleotide sequence encoding a reporter protein. 10. The nucleic acid sequence of claim 1, wherein the Afx response element comprises the nucleotide sequence GTAAACATGTTGT (SEQ ID NO:34). 11. The nucleic acid sequence of claim 1, wherein the Afx response element comprises the nucleotide sequence of any of SEQ ID NOs:1-20. 12. The nucleic acid sequence of claim 1, wherein the Afx response element is operably linked to a nucleotide sequence encoding a protein whose expression is regulated by insulin. 13. The nucleic acid sequence of claim 12, wherein the protein participates in the regulation of glucose transport. 14. The nucleic acid sequence of claim 1, wherein the Afx response element is operably linked to a nucleotide sequence encoding a reporter protein. 15. The nucleic acid sequence of claim 1, wherein the nucleic acid sequence consists of the nucleotide sequence AACATGTT.

Details for Patent 6,472,515

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-08-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-08-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-08-26